Both onset and cessation of menstruation have strong genetic inclination. We aimed to identify genetic factors influencing the onset of menarche and natural menopause in a Japanese population by investigating the polymorphisms of estrogen receptor-␣ and estrogen-metabolizing enzyme genes. Three hundred seventeen postmenopausal Japanese women, aged 46 yr and over, were enrolled in this study under informed consent. Genomic DNA was extracted from peripheral leukocytes, and PCR-based restriction fragment length polymorphism assays were used to determine estrogen receptor-␣: PvuII, XbaI, and estrogen-metabolizing enzymes; CYP17, estrogen biosynthesis (high activity, A2/A2, CYP1A1), hydroxylation (high inducibility, vt/vt, and COMT), inactivation (low activity, L/L) genotypes. There were no significant differences in ages at menarche and natural menopause or years of menstruation among each PvuII or XbaI genotype and seven combinations of PvuII and XbaI genotypes. We found that ages at menarche in women with A1/A2 (higher activity of CYP17; 13.6 ؎ 1.2 yr) were significantly earlier than in those with A1/A1 (lower activity of CYP17; 14.1 ؎ 1.3 yr). There were no significant differences in age at natural menopause and years of menstruation among each CYP17, CYP1A1, or COMT geno A GE AT MENARCHE and/or at menopause and overall years of menstruation have major implications for the health of pre-and postmenopausal women. A genetic influence has been shown to contribute greatly to the timing of onset of the menstrual cycle (1-3). In contrast, very little is known about the possible genetic influences on the timing of menopause. An early onset of menopause is related with higher risks of cardiovascular diseases (4, 5), osteoporosis (6), and ovarian cancer (7), increasing the risks of mortality. Delayed menopause, however, increases the risk of endometrial and breast cancer (8). It is clinically important to identify factors influencing age at menopause. Several environmental factors, such as cigarette smoking (9, 10), nutrition (11), sociodemographic factors (12, 13), and reproductive characteristics (14), have been proposed as risk factors for the early onset of menopause. The reproductive life of one in five women ends prematurely in developed countries, because they have a hysterectomy mainly because of menorrhagia and fibroids before they reach their natural menopause (15), suggesting that genetic factors are involved in the etiology of surgical menopause. Genetic factors have been demonstrated to have some influence on age at menopause (16 -18). A twin study that showed the onset of menopause is genetically determined strongly supports this hypothesis (18) .
A GE AT MENARCHE and/or at menopause and overall years of menstruation have major implications for the health of pre-and postmenopausal women. A genetic influence has been shown to contribute greatly to the timing of onset of the menstrual cycle (1) (2) (3) . In contrast, very little is known about the possible genetic influences on the timing of menopause. An early onset of menopause is related with higher risks of cardiovascular diseases (4, 5) , osteoporosis (6) , and ovarian cancer (7) , increasing the risks of mortality. Delayed menopause, however, increases the risk of endometrial and breast cancer (8) . It is clinically important to identify factors influencing age at menopause. Several environmental factors, such as cigarette smoking (9, 10) , nutrition (11) , sociodemographic factors (12, 13) , and reproductive characteristics (14) , have been proposed as risk factors for the early onset of menopause. The reproductive life of one in five women ends prematurely in developed countries, because they have a hysterectomy mainly because of menorrhagia and fibroids before they reach their natural menopause (15) , suggesting that genetic factors are involved in the etiology of surgical menopause. Genetic factors have been demonstrated to have some influence on age at menopause (16 -18) . A twin study that showed the onset of menopause is genetically determined strongly supports this hypothesis (18) .
Recent studies have shown that estrogen-metabolizing genes are involved in the estrogen-initiating mechanism of tumorigenesis in breast cancer. It is proposed that polymorphisms in the genes involved in estrogen biosynthesis (cytochrome P450c17␣; CYP17), hydroxylation (cytochrome P4501A; CYP1A1), and inactivation of the reactive metabolites (catechol-O-methyltransferase; COMT) may be associated with an elevated risk of breast cancer (19 -21) . There are only a few reports of the association between these polymorphisms and ages at menarche, and there is no report between the polymorphisms and ages at menopause.
Studies of genetic and environmental factors influencing the onset and cessation of menstruation have been mainly performed in a Caucasian population. Recently, genetic variations of the estrogen receptor-␣ (ER␣) genes have been reported to relate to the onset of natural menopause and the risk of surgical menopause in postmenopausal women living in Rotterdam, The Netherlands (22) . Women with the PP genotype had a 1.1-yr earlier onset of menopause than those with the pp genotype (P Ͻ 0.02), showing an allele dose effect that corresponds to a 0.5-yr earlier onset of menopause per copy of the P allele (P Ͻ 0.02). The risk of surgical menopause was 2.4 times higher for women carrying the PP genotype, who underwent hysterectomy due to fibroids or menorrhagia, than for those with the pp genotype. In contrast, the PvuII and XbaI polymorphisms in the ER␣ gene were not associated with the risk of uterine leiomyomas in a large population of Italian women (23) .
The studies are rarely performed in a Japanese population.
Abbreviations: E2, Estradiol; ER␣, estrogen receptor-␣; RFLP, restriction fragment length polymorphism.
The incidence of surgical menopause resulting from menorrhagia and fibroids is not as high in Japanese women compared with that in a Caucasian population. In this study we aimed to identify genetic factors affecting the onset of menarche and natural menopause in healthy postmenopausal Japanese women by investigating polymorphisms of ER␣ genes (PvuII and XbaI) and estrogen-metabolizing enzyme genes (CYP17, CYP1A1 and COMT).
Subjects and Methods Subjects
The study population consisted of 333 postmenopausal Japanese women, aged 46 yr and over, who enrolled among 1100 healthy volunteers in the previous study (24) . For all subjects, a detailed medical history, including menstrual history, was obtained. Of these, 272 women were premenopausal, and 828 were postmenopausal. All of the premenopausal women had regular menstrual cycles, and all of the postmenopausal women reported regular menstrual cycles before natural menopause. Postmenopausal status was defined as no menstrual bleeding for at least 1 yr since the last menstruation. No subject had any history of endocrine or metabolic diseases or was taking any medication, including oral contraceptive pills or estrogen replacement therapy.
Of 828 postmenopausal women, 333 subjects who responded to our follow-up program of bone density measurement were recruited for genotyping of ER␣ and the estrogen-metabolizing enzymes. Of 333 subjects, 11 subjects for whom ages at menarche were 18 yr or greater (diagnosed as primary amenorrhea) and 5 subjects for whom ages at menopause were 40 yr or earlier (diagnosed as premature ovarian failure) were excluded from the study. All gave informed consent before this study.
Genotyping
Genomic DNA was extracted from peripheral leukocytes using a QIAamp blood kit (QIAGEN, Valencia, CA). PCR-based restriction fragment length polymorphism (RFLP) assays were used to determine ER␣ (25) , CYP17 (21, 26) , CYP1A1 (27) , and COMT (19) genotypes of the subjects. To ensure that the observed polymorphisms were specific and were not the results of experimental variation, identical results were obtained by repeating the assay in 100 samples studied.
DNA analysis of the ER␣ genotype was carried out using the method reported by Yaich et al. (25) . The PCR product contains a part of intron 1 and exon 2 of the ER␣ gene and was digested with PvuII or XbaI (Takara, Tokyo, Japan) (28) . The RFLPs were coded as P-p (PvuII) and X-x (XbaI), with uppercase letters signifying the absence and lowercase letters the presence of the restriction site. Genotypes of the estrogenmetabolizing enzymes, CYP17, CYP1A1, and COMT, were determined by digestion with MspAI, MspI, and Hsp92II, respectively. The RFLPs of CYP17, CYP1A1, and COMT were coded as A1-A2 (MspAI), wt-vt (MspI), and H-L (Hsp92II), respectively, with A1, wt, and H showing the absence, and A2, vt, and L the presence of the restriction site (21) . The gene names, the restriction enzymes used for RFLP analysis, the names of specific RFLPs, and the chromosomal location were summarized in Table 1 .
Statistical analysis
Data were expressed as the mean Ϯ sd, with P value less than 0.05 accepted as the value of significance. Differences in anthropometric characteristics, age at menarche and natural menopause, and years of menstruation among the different ER␣ and estrogen-metabolizing enzyme genotypes were tested using ANOVA, followed by Bonferroni's test. All analyses were performed using the Statistical Analysis System (SAS Institute, Inc., Cary, NC).
Results
The age range of the studied women was 46 -77 yr, with a mean age of 59.9 Ϯ 5.8 yr. The background characteristics of the subjects are shown in Table 2 . The mean age at menopause was 50.2 Ϯ 2.9 yr, which is consistent with the report of the Committee of Reproductive Endocrinology of the Japanese Society of Obstetrics and Gynecology published in 1995 that median age at menopause is 50.54 yr.
At the start of this study we analyzed the relationship between age at menopause and smoking in 828 healthy postmenopausal Japanese women (24), of whom 48 (5.8%) were ever-smokers. We defined ever-smokers as those whose cigarette pack-years are more than 20, as calculated by number of smoking years ϫ average number of packs per year; one pack equals 20 cigarettes. There was no significant difference in age at menopause between nonsmokers and ever-smokers (data not shown). It was not feasible to see the association between ages at menopause and smoking in this study.
ER␣ RFLPs
We first determined the associations between ER␣ genotypes and ages at menarche and natural menopause or years of menstruation. The frequencies of ER␣ PvuII and XbaI RFLPs allele in this study were similar to those in other reports in Japanese women (28) ( Table 3 ). The distribution of each genotype followed Hardy-Weinberg equilibrium, which indicates that no selection has occurred among genotypes. We could not find any significant differences in ages at menarche and natural menopause, and years of menstruation among each PvuII and XbaI genotypes. Median ages at menarche and natural menopause were 14.0 and 50.0 yr in each PvuII and XbaI genotype, respectively (Table 3) . We then combined the two RFLPs of ER␣ genotypes together in all subjects and recognized seven genotypes (numbers in parentheses): PPXX (9), PPXx (20) , PPxx (17), PpXx (70), Ppxx (91), ppXx (7), and ppxx (101). Two genotypes (PpXX and ppXX) were not detected in the population examined in this study. There were no significant differences in clinical char- acteristics of all subjects classified by the combination of ER␣ genotypes. We could not find any significant differences in ages at onset and cessation of menstruation, and years of menstruation among seven combinations of PvuII and XbaI genotypes.
CYP17, CYP1A1, and COMT RFLPs
We next asked whether the polymorphisms of estrogenmetabolizing genes are related to the onset, cessation, and the duration of menstruation. The distribution of CYP17 (MspAI) was similar to that of other study in Japanese population (29) ( Table 4 ). The frequencies of each genotype were observed in agreement with Hardy-Weinberg equilibrium. We found that the age at menarche in women with A1/A2 (higher activity of CYP17; 13.6 Ϯ 1.2 yr) was significantly earlier than that in women with A1/A1 (lower activity of CYP17; 14.1 Ϯ 1.3 yr). The age at menarche in women with A2/A2 genotype (13.9 Ϯ 1.3 yr) was earlier than that in women with A1/A1, and the difference did not reach a significant level (Table 4) . There were no significant differences in age at menarche among each CYP1A1 and COMT genotype. Each CYP17, CYP1A1, and COMT genotype did not relate to age at natural menopause and years of menstruation. The median age at menarche was 14.0 yr in each CYP17, CYP1A1, and COMP genotype. The median age at natural menopause was 50.0 yr in each CYP17 and COMP genotype, whereas it differed in CYP1A1 genotypes (51.0 yr in vt/vt genotype and 50.0 yr both in wt/vt and wt/wt genotypes; Table 4 ). We then tried to evaluate the interdependency of each estrogen-metabolizing genotype [low activity COMT (COMT L/L), high inducibility CYP1A1 (CYP1A1 vt/vt), and high activity CYP17 (CYP17 A2/A2)] on ages at menarche and/or natural menopause. Theoretically, there could be 32 potential combinations; however, in this study we had 27 combinations. In addition, in 17 combinations, the number of samples with each combination is less than 8 subjects. We first tried to compare the extreme genotype categories, such as A2/A2L/ Lvt/vt vs. A1/A1H/Hwt/wt genotypes. Unfortunately, the number of women with A2/A2L/Lvt/vt genotypes was 1, and the number of those with A1/A1H/Hwt/wt genotypes was 18, making statistical analysis impractical between the 2 genotype combinations. It was not feasible to analyze the interdependency comparison further in this study.
Discussion
Genetic factors have been shown to be related to ages at menarche and at menopause in family and twin studies (1-3, 16 -18). Highly significant correlations between age at menarche in mothers and daughters and other significant differences in mean menarcheal age between sisters compared with unrelated girls and between MZ and DZ twin pairs have been reported (1) .
First, we asked whether there was an association between age at menarche or natural menopause and ER␣ genotype in healthy postmenopausal Japanese women. The estrogen derived from the ovary not only plays a crucial role as a positive regulation of the preovulatory gonadotropin surge, but also increases its own receptor levels in granulosa cells of the growing follicles. ER␣ is present in various regions of the hypothalamus. Estradiol (E2) induces GnRH release from the hypothalamus and increases the level of GnRH receptors in the anterior pituitary (30) . The deterioration of hypothalamic ER␣ function reduces the positive regulatory effect of E2 on the hypothalamic-pituitary axis, causing a reduction in the frequency and/or amplitude of the preovulatory gonadotropin surge and defective ovulation (31) .
In this investigation we could not find any association between age at natural menopause and ER␣ PvuII and XbaI genotypes in a healthy Japanese population. Neither were ages at menarche associated with the PvuII and XbaI gene polymorphisms. The difference between the Rotterdam study (22) and our results may be partially explained by the difference in genetic backgrounds, Caucasians vs. Asians. Moreover, the population of this study consisted solely of healthy women with natural menopause, whereas the Rotterdam study included women with both natural and surgical menopause.
Secondly, we asked whether ages at menarche and/or natural menopause relate to genotypes of estrogen-metabolizing enzymes in a Japanese population. The breast cancer risk has been shown to be associated with three genotypes of estrogen-metabolizing enzymes and to be highest for low activity COMT (COMT L/L), followed by high inducibility CYP1A1(CYP1A1 vt/vt) and high activity CYP17(CYP17 A2/ A2), genotypes (21) . Further, women with the A2/A2 genotype had elevated levels of estrone and E2 compared with women with the A1/A1 genotype, suggesting that the A2 allele modified endogenous hormone levels (20) . We hypothesized that genotypes of CYP17, CYP1A1, and COMT; estrogen biosynthesis, hydroxylation, and inactivation, respectively, may influence ages at menarche and/or natural menopause, as cigarette smoking increases the risk of early menopause through its effects on inhibition of aromatization and increment of estrogen clearance (32). We could not find any association between age at menopause and estrogenmetabolizing genotypes. On the other hand, we did find the age at menarche in women with the A1/A2 genotype was significantly earlier than that in women with the A1/A1 genotype ( Table 4 ). The menarcheal age in women with the A2/A2 genotype was earlier than in those with A1/A1 genotype and the difference did not reach a significant level. These suggest that higher activity of CYP17 (A2 allele) may contribute to the earlier onset of menstruation in Japanese population. Interestingly, median age at menarche did not differ among each CYP17 genotype. Among control subjects in the studies of breast cancer, the mean age of menarche in women carrying A1/A1 was statistically significantly higher Gorai et al.
• than that in women carrying the A2 allele (13.4 vs. 13.0 yr; P ϭ 0.047) in one study (26) , whereas the median age at menarche did not differ significantly by genotype (A1/A1, 13.0 yr; A1/A2ϩA2/A2, 12.0 yr; P ϭ 0.97) in another study (20) . The result of this study is consistent with that of the former study, but not with the latter. Ovarian steroids, E2 and progesterone, can modulate the release of pituitary gonadotropins by negative and positive feedback effects exerted at the level of the anterior pituitary and hypothalamus (33) , indicating that estrogen-metabolizing enzymes may influence the timing of menarche. The higher activity of CYP17 (A2 allele), the lower activity of COMT (L allele), and the higher inducibility of CYP1A1 (vt allele) may influence earlier ages at menarche, as the ages at menarche in women with A1/A2 genotype were significantly earlier than in those with A1/A1 genotype. We could not analyze the interdependency of each estrogen-metabolizing genotype, including extreme genotype categories such as A2/A2L/Lvt/vt vs. A1/A1H/Hwt/wt, on ages at menarche and/or natural menopause, because of the small sample sizes of women with these genotypes. The interrelationships between combinations of each estrogen-metabolizing genotype and ages at menarche and/or natural menopause remain to be elucidated in future studies until a larger sample size is obtained, and a comparison of the extreme genotype categories is performed.
This study has several limitations. First, there may have been bias due to incorrectness in self-report of the ages at menarche and/or menopause. However, this bias does not seem to differ between each ER␣ and estrogen-metabolizing genotypes. We could not find any difference in the number of answered questions between the groups. Second, our subjects were community dwelling, and therefore our results may not apply to other populations in Japan. Nevertheless, the distributions of ER␣ PvuII, XbaI, and estrogen hydroxylation CYP17 were similar to those in other reports of Japanese women (28, 29) , suggesting the applicability of our results to other Japanese populations. Third, the number of women in the study population is rather small for such an analysis, which makes difficult a detailed analysis of the association between minor genotypes and ages at menarche and/or menopause.
In summary, estrogen-metabolizing CYP17 (A2 allele) may influence age at menarche in healthy postmenopausal Japanese women.
